Spruce Biosciences, Inc. Payments to Acquire Investments
Spruce Biosciences, Inc. (SPRB) reported Payments to Acquire Investments of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-04-15.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2025-04-15
- Spruce Biosciences, Inc. payments to acquire investments for the quarter ending 2024-12-31 was $0.00.
- Spruce Biosciences, Inc. payments to acquire investments for the quarter ending 2024-09-30 was $0.00.
- Spruce Biosciences, Inc. payments to acquire investments for the quarter ending 2024-06-30 was $0.00.
- Spruce Biosciences, Inc. payments to acquire investments for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Spruce Biosciences, Inc. payments to acquire investments for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Spruce Biosciences, Inc. payments to acquire investments for fiscal 2023 was $11.88M, a 67.71% decline from fiscal 2022.
- Spruce Biosciences, Inc. payments to acquire investments for fiscal 2022 was $36.80M, a 53.46% decline from fiscal 2021.
- Spruce Biosciences, Inc. payments to acquire investments for fiscal 2021 was $79.08M.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $0.00 derived: sum of 2 quarters · filed 2025-04-15 | $0.00 derived: sum of 3 quarters · filed 2025-04-15 | $0.00 10-K · filed 2025-04-15 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 4 quarters · filed 2025-04-15 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $0.00 10-Q · filed 2024-08-12 | $0.00 derived: sum of 3 quarters · filed 2025-04-15 | $0.00 derived: sum of 4 quarters · filed 2025-04-15 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-13 | $0.00 derived: sum of 2 quarters · filed 2025-04-15 | $0.00 derived: sum of 3 quarters · filed 2025-04-15 | $0.00 derived: sum of 4 quarters · filed 2025-04-15 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $0.00 derived: sum of 2 quarters · filed 2025-04-15 | $0.00 derived: sum of 3 quarters · filed 2025-04-15 | $11.88M 10-K · filed 2025-04-15 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $11.88M 10-Q · filed 2024-11-12 | $14.81M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $11.88M 10-Q · filed 2024-08-12 | $14.81M derived: sum of 3 quarters · filed 2024-08-12 | $35.70M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $11.88M 10-Q · filed 2024-05-13 | $14.81M derived: sum of 2 quarters · filed 2024-05-13 | $35.70M derived: sum of 3 quarters · filed 2024-05-13 | $37.69M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $2.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $23.82M derived: sum of 2 quarters · filed 2024-03-18 | $25.81M derived: sum of 3 quarters · filed 2024-03-18 | $36.80M 10-K · filed 2024-03-18 |
| 2022-09-30 | $20.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $22.88M derived: sum of 2 quarters · filed 2023-11-13 | $33.87M 10-Q · filed 2023-11-13 | $39.85M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $12.98M 10-Q · filed 2023-08-14 | $18.95M derived: sum of 3 quarters · filed 2023-08-14 | $31.23M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $10.99M 10-Q · filed 2023-05-15 | $16.97M derived: sum of 2 quarters · filed 2023-05-15 | $29.24M derived: sum of 3 quarters · filed 2023-05-15 | |
| 2021-12-31 | $5.98M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $18.25M derived: sum of 2 quarters · filed 2023-03-16 | $79.08M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $12.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $73.10M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $60.83M 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |